Equine NGAL antibody and antigen (recombinant protein)
Diagnostic anti-Equine NGAL antibodies pairs and antigen for animal health (animal Equine/Horse kidney injury) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-EQU-NGAL-Ag01 | Recombinant Equine NGAL protein | 3090 |
GMP-EQU-NGAL-Ab01 | Anti-Equine NGAL mouse monoclonal antibody (mAb) | 1953 |
GMP-EQU-NGAL-Ab02 | Anti-Equine NGAL mouse monoclonal antibody (mAb) | 1953 |
GMP-EQU-NGAL-Ab03 | Anti-Equine NGAL human monoclonal antibody (mAb) | 1953 |
GMP-EQU-NGAL-Ab04 | Anti-Equine NGAL human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-EQU-NGAL-Ag01 |
Product Name | Recombinant Equine NGAL protein |
Target/Biomarker | Equine Neutrophil gelatinase-associated lipocalin (NGAL) |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Equine Neutrophil gelatinase-associated lipocalin antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NGAL level test of animal Equine/Horse with kidney injury. |
Tag | His |
Products description | Recombinant Equine NGAL protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-EQU-NGAL-Ab01, GMP-EQU-NGAL-Ab02 |
Product Name | Anti-Equine NGAL mouse monoclonal antibody (mAb) |
Target/Biomarker | Equine Neutrophil gelatinase-associated lipocalin (NGAL) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Equine Neutrophil gelatinase-associated lipocalin antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies in NGAL level test of animal Equine/Horse with kidney injury. |
Tag | mFc |
Products description | Anti-Equine NGAL mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-EQU-NGAL-Ab03, GMP-EQU-NGAL-Ab04 |
Product Name | Anti-Equine NGAL human monoclonal antibody (mAb) |
Target/Biomarker | Equine Neutrophil gelatinase-associated lipocalin (NGAL) |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Recombinant Equine Neutrophil gelatinase-associated lipocalin antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies in NGAL level test of animal Equine/Horse with kidney injury. |
Tag | hFc |
Products description | Anti-Equine NGAL human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-NGAL antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Equine/Horse Neutrophil Gelatinase-Associated Lipocalin (NGAL) emerges as a captivating biomarker, offering insights into the complex web of equine health and disease. Structurally, NGAL belongs to the lipocalin protein family, characterized by its ability to bind to and transport hydrophobic molecules. Within the equine body, NGAL's origin is multifaceted, originating primarily from neutrophils, the vanguards of the equine immune system, and renal tubular cells. Neutrophils, the first responders to threats in the equine immune system, store NGAL in specific granules within these white blood cells. This strategic positioning allows NGAL to be rapidly deployed upon neutrophil activation, ensuring a swift response to cellular stressors and infections. Additionally, NGAL is expressed by renal tubular cells, further expanding its significance. When faced with inflammation, oxidative stress, or nephrotoxic insults, renal tubular cells release NGAL into the urine. This dual source—neutrophils and renal tubular cells—renders NGAL readily detectable in both blood and urine, amplifying its utility as a versatile biomarker.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.